Chase Investment Counsel’s Vicarious Surgical RBOT Stock Holding History

Chase Investment Counsel’s Portfolio RBOT Stock Details RBOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,204	Closed	-$383K	–	140
2021 Q4	$383K	Hold	1,204	–	–	0.15%	82
2021 Q3	$540K	Buy	+1,204	New	+$381K	0.23%	60

Other funds holding RBOT

VK Services Menlo Park, California $1.01M AUM 157.81% 1-Year Est. Return

AMH

Aspex Management (HK) Central, Hong Kong $8.89B AUM 39.91% 1-Year Est. Return

CFM

Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VIA

Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return

DDD Partners Bellevue, Washington $1.6B AUM 17.6% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MAM

Maytree Asset Management Hong Kong $154M AUM 453.79% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Chase Investment Counsel's RBOT Position: Q1 2022 in Review

Chase Investment Counsel sold out of Vicarious Surgical (RBOT) in Q1 2022, closing a stake of 1,204 shares — an estimated $383K sold.

Chase Investment Counsel first reported a position in RBOT in Q3 2021 and held it in 2 quarters. The position peaked at $540K in Q3 2021. 61 funds tracked by Wall St. Rank hold RBOT as of Q1 2022.

Chase Investment Counsel reported no remaining Vicarious Surgical position as of Q1 2022 after selling out during the quarter.
Chase Investment Counsel sold 1,204 Vicarious Surgical shares in Q1 2022, an estimated $383K.
Chase Investment Counsel first reported a position in Vicarious Surgical in Q3 2021 and held it in 2 quarters.
Chase Investment Counsel's Vicarious Surgical position peaked at $540K in Q3 2021.
61 funds tracked by Wall St. Rank held Vicarious Surgical as of Q1 2022.

Based on Chase Investment Counsel's 13F filing for Q1 2022, filed 21 Apr 2022.